Skip to main content
. Author manuscript; available in PMC: 2015 Jul 7.
Published in final edited form as: Clin Cancer Res. 2012 May 25;18(12):3396–3406. doi: 10.1158/1078-0432.CCR-11-2703

Figure 1.

Figure 1

Pharmacokinetics of bardoxolone methyl. A, mean plasma concentration-time profiles for the first (circles) and last (squares) dose of bardoxolone methyl in the cohort of patients receiving 900 mg/d. Error bars depict the SD of the mean concentration of bardoxolone methyl in plasma for the day 21 dose. B, relationship between the apparent oral clearance (CL/F) of bardoxolone methyl and dose. C, relationship between the biological half-life (t1/2,z) of bardoxolone methyl and dose. B and C, data points are the observed values in individual patients and the solid lines were generated by linear regression analysis of the data.